Compare Crispr Therapeutics AG (CRSP) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Marathon Petroleum Corp — how do they compare? Crispr Therapeutics AG trades at $50.91 (market cap $4.97B), while Marathon Petroleum Corp trades at $303.97 (market cap $88.57B). The key difference: Marathon Petroleum Corp is far larger — about 17.8× Crispr Therapeutics AG's market cap, and Marathon Petroleum Corp pays a 1.29% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MPC | |
|---|---|---|
Market Cap | $4.97B | $88.57B |
Sector | Health | Energy |
52-Week High | $76.78 | $303.40 |
52-Week Low | $44.34 | $158.59 |
Enterprise Value | $3.32B | $120.75B |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Marathon Petroleum (MPC) trades at $296.88, up 4.63% today and near its 52-week high. The stock shows strong momentum with bullish moving averages and a consensus analyst rating of Buy (75.76%). Recent earnings beat expectations in Q4 2025 and Q1 2026, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. The company maintains solid profitability with a 3.42% net margin and 27.92% ROE, supported by a dividend payment of $1.00 scheduled for June 2026.
MPC's outlook is positive due to elevated refining margins and analyst optimism, but risks include volatile oil prices, legal challenges over AI pricing allegations, and declining revenue trends. The stock trades above the consensus price target of $292.70, suggesting limited near-term upside despite strong institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
